Cymabay therapeutics, inc. (CBAY)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Collaboration revenue

-

-

10,000

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

3,050

Operating expenses:
Research and development

83,837

58,124

18,938

15,941

17,026

15,823

4,525

9,280

General and administrative

19,238

14,381

12,387

9,645

8,871

8,185

4,871

4,208

Restructuring charges

5,075

-

-

-

-

-

-

-

Total operating expenses

108,150

72,505

31,325

25,586

25,897

24,008

9,396

13,488

Loss from operations

-108,150

-72,505

-21,325

-25,586

-25,897

-24,008

-9,396

-10,438

Other income (expense):
Interest income

5,342

3,988

621

176

160

74

10

22

Interest expense

-

336

1,080

1,337

913

755

822

841

Loss on extinguishment of debt

-

-407

-

-

-

-

-

-

Other expense, net

-

-3,288

-5,773

76

11,121

-7,228

135

2

Total other income (expense)

5,342

-43

-6,232

-1,085

-

-

-

-

Net loss

-102,800

-72,548

-27,557

-26,671

-15,529

-31,917

-10,073

-11,255

Net (loss) income attributable to common stockholders

-

-

-

-

-

-

243,994

-23,899

Net loss

-102,800

-72,548

-27,557

-26,671

-15,529

-31,917

-10,073

-11,255

Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities

138

-14

-43

20

-7

-16

2

-2

Total other comprehensive (loss) income

138

-14

-43

20

-7

-16

2

-2

Comprehensive loss

-102,670

-72,562

-27,600

-26,651

-15,536

-31,933

-10,071

-11,257

Basic net loss per common share

-1.53

-1.25

-0.79

-1.14

-0.82

-2.65

103.52

-4,128.71

Diluted net loss per common share

-1.53

-1.26

-0.79

-1.14

-0.83

-2.65

-3.54

-4,128.71

Weighted average common shares outstanding used to calculate basic net loss per common share

67,033

57,808

34,903

23,447

18,900

12,048

2,357

5

Weighted average common shares outstanding used to calculate diluted net loss per common share

67,033

57,838

34,903

23,447

18,917

12,048

2,845

5